stockrowREGENXBIO Inc.
RGNXREGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
- Revenue
- −69.2%
- EPS
- +48.0%
- Free cash flow
- +168.1%
Quarter to September 2026, against a year earlier
Follow RGNX
Alert me
REGENXBIO Inc. (RGNX) Return on invested capital
REGENXBIO Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −584.2% (fiscal 2024) to 32.6% (fiscal 2021); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 584.21 |
| FY2024 | −584.2% | (124.89) |
| FY2023 | −459.3% | (350.91) |
| FY2022 | −108.4% | (140.99) |
| FY2021 | 32.6% | 32.58 |
| FY2020 | 0.00% | 60.48 |
| FY2019 | −60.5% | (88.73) |
| FY2018 | 28.3% | 241.40 |
| FY2017 | −213.2% | (156.58) |
| FY2016 | −56.6% | (42.49) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DMAC DiaMedica Therapeutics, Inc. compare | 0.00% |
| VALN Valneva SE Sponsored ADR compare | 0.00% |
| SLBT SL SCIENCE HLDG compare | 0.00% |
| STTK Shattuck Labs, Inc. compare | 0.00% |
| NGNE Neurogene Inc. compare | 0.00% |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | 0.00% |
| RGNX REGENXBIO Inc. | 0.00% |
| OVID Ovid Therapeutics compare | −35.1% |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)